EP0868515A1 - Komponente eines signalübertragungssystems von staphylococcus. - Google Patents

Komponente eines signalübertragungssystems von staphylococcus.

Info

Publication number
EP0868515A1
EP0868515A1 EP96943225A EP96943225A EP0868515A1 EP 0868515 A1 EP0868515 A1 EP 0868515A1 EP 96943225 A EP96943225 A EP 96943225A EP 96943225 A EP96943225 A EP 96943225A EP 0868515 A1 EP0868515 A1 EP 0868515A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
polynucleotide
dna
seq
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96943225A
Other languages
English (en)
French (fr)
Inventor
Nicola Wallis
John Edward Hodgson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0868515A1 publication Critical patent/EP0868515A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention relates generally to newly identified polynucleotides and polypeptides in the family of the DegU response regulatory protein from Bacillus subtilis.
  • TCS signal transduction systems
  • DegU is the response regulator of the Deg TCSTS which is involved in the production of extracellular proteases (Henner, D.J., et al, ( 1988) . Bacteriol, 170, 5102-
  • Histidine kinases are components of the TCSTS which autophosphorylate at a histidine residue. The phosphate group is then transferred to the cognate response regulator.
  • the histidine kinases have five short conserved amino acid sequences (Stock, J. B. et al, Microbioi. Rev. 53, 450-490; Swanson. R.V. et al. ( 1994) TIBS, 19, 485-491). These are the histidine residue, which is phosphorylated, followed by a conserved asparagine residue after approximately 100 residues. After another 15 to 45 residues a DXGXG motif is found, followed by a FXXF motif after another 10-20 residues. Ten to twenty residues further on another glycine motif, GXG is found. The two glycine motifs are thought to be involved in nucleotide binding.
  • TCSTS processes regulated by TCSTS are production of virulence factors, motility, antibiotic resistance and cell replication. Inhibitors of TCSTS proteins would prevent the bacterium from establishing and maintaining infection of the host by preventing it from producing the necessary factors for pathogenesis and thereby have utility in anti ⁇ bacterial therapy.
  • polypeptides inter alia, that have been identified as novel peptides by comparison between the amino acid sequence set out in Figure 2 and known amino acid sequences of other proteins such as DegU protein.
  • the polynucleotide comprises the region encoding the novel polypeptides in the sequence set out in Figure 1 [SEQ ID NO: 1 ], or a fragment, analogue or derivative thereof.
  • an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus DNA contained in the National Collection of Industrial and Marine Bacteria Ltd. (NCIMB), Aberdeen, Scotland under number NCIMB 40771 on 1 1 September 1995.
  • isolated nucleic acid molecules encoding novel polypeptides, including mRNAs, cDNAs, genomic DNAs and, in further embodiments of this aspect of the invention include biologically, diagnosticaliy, prophylactically, clinically or therapeutically useful variants, analogs or derivatives thereof, or fragments thereof, including fragments of the variants, analogs and derivatives, and compositions comprising same.
  • a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.
  • particularly preferred embodiments of this aspect of the invention are naturally occurring allelic variants of the novel nucleic acid sequences and polypeptides encoded thereby.
  • novel polypeptide characterized by the amino acid sequence of SEQ ID NO:2, as well as biologically, diagnosticaliy, prophylactically, clinically or therapeutically useful fragments, variants and derivatives thereof, variants and derivatives of the fragments, and analogs of the foregoing, and compositions comprising same.
  • variants of the polypeptide encoded by naturally occurring alleles of the gene of the invention which is characterized by the nucleic acid sequences of SEQ ID NO: 1.
  • inhibitors to such polypeptides useful as antibacterial agents, including, for example, antibodies.
  • products, compositions and methods inter alia: assessing expression; to treat and prevent bacterial infections; assaying genetic variation; and administering a novel polypeptide or polynucleotide of the invention to an organism to raise an immunological response against bacteria, especially Staphylococcus.
  • polynucleotides that hybridize to the novel polynucleotide sequences of the invention, including SEQ ID NO: 1.
  • antibodies against the polypeptides of the invention are provided.
  • agonists to the polynucleotides and/or polypeptides of the invention which are also preferably bacteriostatic or bacteriocidal.
  • antagonists to the polynucleotides and/or polypeptides of the invention which are also preferably bacteriostatic or bacteriocidal.
  • compositions comprising a polynucleotide or a polypeptide of the invention for administration to a cell or to a multicellular organism.
  • This invention relates generally to newly identified polynucleotides and polypeptides of the response regulator, and more particularly the DegU family. Also encompassed by this invention are variants and derivatives of these polynucleotides and polypeptides; processes for making these polynucleotides and these polypeptides, and their variants and derivatives; agonists and antagonists of the polypeptides; and uses of these polynucleotides, polypeptides, variants, derivatives, agonists and antagonists.
  • the invention relates to a novel response regulator protein from Staphylococcus aureus WCUH29, characterized in that it comprises the amino acid sequence given in SEQ ID NO: 2 or a fragment, analogue or derivative thereof.
  • polynucleotides (DNA or RNA) which encode such polypeptides.
  • FIG. 1 provides the nucleic acid sequences [SEQ ID NO: 1 ] of the gene of the invention.
  • Fig. 2 provides the amino acid sequences [SEQ ID NO:2] of a polypeptide of the invention.
  • BINDING MOLECULE refers to molecules or ions which bind or interact specifically with the polypeptides or polynucleotides of the present invention, including, for example enzyme substrates, cell membrane components and classical receptors.
  • Binding between polypeptides of the invention and such molecules, including binding or interaction molecules may be exclusive to polypeptides of the invention, which is preferred, or it may be highly specific for polypeptides of the invention, which is also preferred, or it may be highly specific to a group of proteins that includes polypeptides of the invention, which is preferred, or it may be specific to several groups of proteins at least one of which includes a polypeptide of the invention.
  • Binding molecules also include antibodies and antibody-derived reagents that bind specifically to polypeptides of the invention.
  • GENETIC ELEMENT generally means a polynucleotide comprising a region that encodes a polypeptide or a polynucleotide region that regulates replication, transcription or translation or other processes important to expression of the polypeptide in a host cell, or a polynucleotide comprising both a region that encodes a polypeptide and a region operably linked thereto that regulates expression.
  • Genetic elements may be comprised within a vector that replicates as an episomai element; that is, as a molecule physically independent of the host cell genome. They may be contained within plasmids. Genetic elements also may be comprised within a host cell genome; not in their natural state but, rather, following manipulation such as isolation, cloning and introduction into a host cell in the form of purified DNA or in a vector, among others.
  • a cell has been TRANSFORMED by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane.
  • Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
  • the exogenous DNA may be maintained on an episomai element, such as a plasmid.
  • a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the exogenous DNA.
  • HOST CELL is a cell which has been transduced, transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
  • a CLONE is a population of cells derived from a single cell or common ancestor by mitosis.
  • a CELL LINE is a clone of a primary cell that is capable of stable growth in vitro for many generations.
  • REPLICON is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
  • VECTOR is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
  • DOUBLE-STRANDED DNA MOLECULE refers to the polymeric form of deoxyribonucleotides (bases adenine, guanine, thymine, or cytosine) in a double-stranded helix, both relaxed and supercoiled. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
  • linear DNA molecules e.g., restriction fragments
  • sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA).
  • a DNA CODING SEQUENCE OF or a NUCLEOTIDE SEQUENCE ENCODING a particular protein is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.
  • PROMOTER SEQUENCE is a DNA regulatory region capable of binding RNA poiymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence.
  • the promoter sequence is bound at the 3' terminus by a translation start codon (e.g., ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
  • a transcription initiation site (conveniently defined by mapping with nuclease
  • Eukaryotic promoters will often, but not always, contain "TATA” boxes and "CAT” boxes.
  • Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
  • DNA CONTROL SEQUENCES refers collectively to promoter sequences, ⁇ bosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (1 e , the transcription and translation) of a coding sequence in a host cell
  • a control sequence directs the expression of a coding sequence in a cell when RNA poiymerase will bind the promoter sequence and transc ⁇ be the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence
  • DIGESTION of DNA refers to catalytic cleavage of the DNA with a rest ⁇ ction enzyme that acts only at certain sequences in the DNA
  • the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan.
  • plasmid or DNA fragment typically 1 ⁇ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ⁇ l of buffer solution
  • isolating DNA fragments for plasmid construction typically 5 to 50 ⁇ g of DNA are digested with 20 to 250 units of enzyme in a larger volume
  • Approp ⁇ ate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer
  • Incubation times of about 1 hour at 37° C are ordinarily used, but may vary in accordance with the supplier's instructions
  • the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel desc ⁇ bed by Goeddel, D et al , (1980) Nucleic Acids Res , 8, 4057
  • a HETEROLOGOUS region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature
  • IDENTITY or SIMILARITY are relationships between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences Both identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A M , ed , Oxford University Press, New York, 1988; Biocomputtng Informatics and Genome Projects, Smith, D W , ed ,
  • Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al, (1984) Nucleic Acids Research 12(1), 387), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al, (1990) J. Molec. Biol 215, 403).
  • ISOLATED means altered "by the hand of man” from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both.
  • a naturally occurring polynucleotide or a polypeptide naturally present in a living organism in its natural state is not “isolated”, but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.
  • such polynucleotides can be joined to other polynucleotides, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance.
  • the isolated polynucleotides can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment.
  • the polynucleotides and polypeptides may occur in a composition, such as media formulations, solutions for introduction of polynucleotides or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated polynucleotides or polypeptides within the meaning of that term as it is employed herein.
  • POLYNUCLEOTIDE(S) generally refers to any polyribonucleotide or polydeoxribo ⁇ ucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and t ⁇ ple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hyb ⁇ d molecules comp ⁇ sing DNA and RNA that may be single-stranded or, more typically, double-stranded, or t ⁇ ple- stranded, or a mixture of single- and double-stranded regions
  • polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA The strands in such regions may be from the same molecule
  • RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as t ⁇ tylated bases, to name just two examples, are polynucleotides as the term is used herein It will be appreciated that a great va ⁇ ety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art
  • polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia Polynucleotides embraces short polynucleotides often referred to as ol ⁇ gonucleot ⁇ de(s)
  • LIGATION refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T , et al , Id , p 146) Unless otherwise provided, ltgation may be accomplished using known buffers and conditions with 10 units to T4 DNA hgase ("ligase") per 0 5 ⁇ g of approximately equimolar amounts of the DNA fragments to be ligated
  • POLYPEPTIDES includes all polypeptides as desc ⁇ bed below
  • the basic structure of polypeptides is well known and has been desc ⁇ bed in innumerable textbooks and other publications in the art
  • the term is used herein to refer to any peptide or protein comprising two or more amino acids joined to each other in a linear chain by peptide bonds
  • the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types
  • polypeptides often contain amino acids other than the 20 ammo acids commonly referred to as the 20 naturally occurring amino acids, and that many amino acids, including the terminal amino acids, may be modified in a given polypeptide, either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques which are well known to the art.
  • polypeptides are not always entirely linear.
  • polypeptides may be generally as a result of posttranslational events, including natural processing event and events brought about by human manipulation which do not occur naturally.
  • Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occur ⁇ ng and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well For instance, the ammo terminal residue of polypeptides made in E colt or other cells, prior to proteolytic processing, almost invariably will be N-formylmethionine During post-translational modification of the peptide, a methionine residue at the NH 2 -term ⁇ nus may be deleted Accordingly, this invention contemplates the use of both the methionine-containing and the methionineless ammo terminal va ⁇ ants of the protein of the invention
  • nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a polypeptide that differs in amino acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference and the variant are closely similar overall and. in many regions, identical.
  • a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.
  • the invention relates to a novel response regulator protein from Staphylococcus aureus, characterized in that it comprises the amino acid sequence given in SEQ ID NO: 2 or a fragment, analogue or derivative thereof.
  • polypeptide(s) will be used to refer to the response regulator protein, its fragments, analogues or derivatives as well as the polypeptide fragment or its derivatives.
  • the invention relates especially to the gene having the nucleotide and amino acid sequences set out in Figure 1 and Figure 2 respectively, and to the nucleotide and amino acid sequences of the DNA of S. aureus WCUH 29 which has been deposited at the National Collection of Industrial and Marine Bacteria Ltd. (NCIMB), Aberdeen, Scotland under number NCIMB 40771 on 1 1 September 1995. This is herein referred to as "the deposited DNA”.
  • the nucleotide and amino acid sequences set out in Figure 1 [SEQ ID NO: l ] and 2 [SEQ ID NO:2] were obtained by sequencing the DNA of the deposit.
  • the sequence of the deposit is controlling as to any discrepancies between it (and the sequence it encodes) and the sequences of Figure 1 [SEQ ID NO: 1 ] and Figure 2 [SEQ ID NO:2j.
  • Signature Tagged Mutagenesis T is technique is described by Hensel et al, ( 1995) Science 269, 400-403, the content of which is incorporated by reference for background purposes.
  • Signature tagged mutagenesis identifies genes necessary for the establishment/maintenance of infection in a given infection model.
  • the basis of the technique is the random mutagenesis of a target organism by various means (e.g., transposons) such that unique DNA sequence tags are inserted in close proximity to the site of mutation.
  • the tags from a mixed population of bacterial mutants and bacteria recovered from infected hosts are detected by amplification, radiolabeling and hybridization analysis. Mutants attenuated in virulence are revealed by absence of the tag from the pool of bacteria recovered from infected hosts.
  • random chromosomal fragments of target organism are cloned upstream of a promoter-less reporter gene in a plasmid vector.
  • the pool is introduced into a host and at various times after infection bacteria may be recovered and assessed for the presence of reporter gene expression.
  • the chromosomal fragment carried upstream of an expressed reporter gene should carry a promoter or portion of a gene normally upregulated during infection. Sequencing upstream of the reporter gene allows identification of the up regulated gene.
  • transposons carrying controllable promoters which provide transcription outward from the transposon in one or both directions, are generated. Random insertion of these transposons into target organisms and subsequent isolation of insertion mutants in the presence of inducer of promoter activity ensures that insertions which separate promoter from coding region of a gene whose expression is essential for cell viability will be recovered. Subsequent replica plating in the absence of inducer identifies such insertions, since they fail to survive. Sequencing of the flanking regions of the transposon allows identification of the site of insertion and identification of the gene disrupted. Close monitoring of the changes in cellular processes/morphology during growth in the absence of inducer yields information on likely function of the gene.
  • Such monitoring could include flow cytometry (cell division, lysis, redox potential, DNA replication), incorporation of radiochemically labeled precursors into DNA, RNA, protein, lipid, peptidoglycan, monitoring reporter enzyme gene fusions which respond to known cellular stresses.
  • flow cytometry cell division, lysis, redox potential, DNA replication
  • incorporation of radiochemically labeled precursors into DNA, RNA, protein, lipid, peptidoglycan monitoring reporter enzyme gene fusions which respond to known cellular stresses.
  • bacte ⁇ al infected tissue e g , 48 hour mu ⁇ ne lung infections
  • the amount of each mRNA species assessed by reverse transcription of the RNA sample primed with random hexanucleotides followed by PCR with gene specific p ⁇ mer pairs
  • the determination of the presence and amount of a particular mRNA species by quantification of the resultant PCR product provides information on the bacte ⁇ al genes which are transcribed in the infected tissue Analysis of gene transcription can be carried out at different times of infection to gam a detailed knowledge of gene regulation in bacterial pathogenesis allowing for a clearer understanding of which gene products represent targets for screens for novel antibacte ⁇ als
  • the bacte ⁇ al mRNA preparation need not be free of mammalian RNA This allows the investigator to carry out a simple and quick RNA preparation from infected tissue to obtain bacte ⁇ al mRNA
  • TRIzole reagent and DNAase treatment to remove contaminating DNA Preferably the process is optimized by finding those conditions which give a maximum amount of bacte ⁇ al 16S ⁇ bosomal RNA, preferably that of Stapylococcus aureus, as detected by probing Northerns with a suitably labeled sequence specific oligonucleotide probe
  • a 5' dye labelled p ⁇ mer is used in each PCR primer pair in a PCR reaction which is terminated optimally between 8 and 25 cycles
  • the PCR products are separated on 6% polyacrylamide gels with detection and quantification using GeneScanner (manufactured by ABI)
  • polynucleotides which encode the polypeptide having the deduced amino acid sequence of Figure 2 [SEQ ID NO:2].
  • polynucleotide encoding a polypeptide encompasses polynucleotides which include a sequence encoding a polypeptide of the present invention, particularly bacterial, and more particularly the polypeptide of the invention having the amino acid sequence set out in Figure 2 [SEQ ID NO:2].
  • the term encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.
  • a polynucleotide of the present invention encoding SEQ ID NO:2 or a fragment thereof may be obtained using standard cloning and screening procedures, such as those for cloning and sequencing chromosomal DNA fragments from Staphylococcus aureus cells as starting material, followed by obtaining a full length clone.
  • a library of clones of chromosomal DNA of Staphylococcus aureus in E.coli or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence.
  • a radiolabeled oligonucleotide preferably a 17-mer or longer, derived from a partial sequence.
  • Clones carrying DNA identical to that of the probe can then be distinguished using high stringency washes.
  • sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ( 1989). (See, Screening By Hybridization 1.90 and Sequencing
  • the gene of the invention [SEQ ID NO: 1] is structurally related to other response regulators, as shown by the results of sequencing of the gene characterized by the DNA of the deposited S. aureus WCUH 29.
  • the DNA sequence thus obtained is set out in Figure 1 [SEQ ID NO: 1 ]. It contains an open reading frame encoding a protein of having about the number of amino acid residues set forth in Figure 2 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art.
  • the polypeptide of Figure 2 [SEQ ID NO:2] has about 28% identity to the DegU regulatory protein from Bacillus subtilis.
  • Polynucleotides of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof.
  • the DNA may be double-stranded or single-stranded.
  • Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.
  • sequence which encodes the polypeptide may be identical to the coding sequence of the polynucleotide shown in Figures 1 [SEQ ID NO:l ]. It also may be a polynucleotide with a different sequence, which, as a result of the redundancy (degeneracy) of the genetic code, encodes the polypeptide of Figure 2 [SEQ ID NO:2].
  • Polynucleotides of the present invention which encode the polypeptide of Figure 2 [SEQ ID NO:2] may include, but are not limited to the coding sequence for the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional coding sequences, such as those encoding a leader or secretory sequence, such as a pre-, or pro- or prepro- protein sequence; the coding sequence of the mature polypeptide, with or without the aforementioned additional coding sequences, together with additional, non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription (including termination signals, for example), ribosome binding, mRNA stability elements, and additional coding sequence which encode additional amino acids, such as those which provide additional functionalities.
  • the polypeptide may be fused to a marker sequence, such as a peptide, which facilitates purification of the fused polypeptide.
  • the marker sequence is a hexa- histidine peptide, such as the tag provided in the pQE vector (Qiagen, Inc.), among others, many of which are commercially available.
  • hexa-histidine provides for convenient purification of the fusion protein.
  • the HA tag may also be used to create fusion proteins and corresponds to an epitope derived of influenza hemagglutinin protein, which has been described by Wilson et al, ( 1984) Cell 37, 767, for instance.
  • Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated genetic elements.
  • the present invention further relates to va ⁇ ants of the herein above described polynucleotides which encode fragments, analogs and derivatives of the polypeptide having the deduced ammo acid sequence of Figure 2 [SEQ ID NO 2]
  • a variant of the polynucleotide may be a naturally occurring variant such as a naturally occurring allelic va ⁇ ant, or it may be a va ⁇ ant that is not known to occur naturally
  • Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques, including those applied to polynucleotides, cells or organisms
  • variants in this regard are variants that differ from the aforementioned polynucleotides by nucleotide substitutions, deletions or additions
  • the substitutions, deletions or additions may involve one or more nucleotides
  • the va ⁇ ants may be altered in coding or non-coding regions or both Alterations in the coding regions may produce conservative or non-conservative ammo acid substitutions, deletions or additions
  • polynucleotides encoding va ⁇ ants, analogs, derivatives and fragments of SEQ ID NO 1 , and variants, analogs and de ⁇ vatives of the fragments which have the ammo acid sequence of the polypeptide of Figure 2 [SEQ ID NO.2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no am o acid residues are substituted, deleted or added, in any combination Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the gene of SEQ ID NO:l Also especially preferred in this regard are conservative substitutions Most highly preferred are polynucleotides encoding polypeptides having the ammo acid sequence of Figure 2 [SEQ ID NO 2], without substitutions
  • polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding the polypeptide having the amino acid sequence set out in Figure 2 [SEQ ID N0 2], and polynucleotides which are complementary to such polynucleotides
  • polynucleotides that comp ⁇ se a region that is at least 80% identical over their entire length to a polynucleotide encoding the polypeptide of the DNA of the deposited S aureus WCUH 29 and polynucleotides complementary thereto
  • polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred
  • those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.
  • polypeptides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the polypeptide characterized by the deduced amino acid sequence of SEQ ID NO: 2.
  • Preferred embodiments in this respect are polynucleotides which encode polypeptides which retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Figure 1 [SEQ ID NO: l].
  • the present invention further relates to polynucleotides that hybridize to the herein above-described sequences.
  • the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides.
  • stringent conditions means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
  • polynucleotides of the invention may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding the sequences of SEQ ID NO: 1 and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to SEQ ID NO: 1.
  • Such probes generally will comprise at least 15 bases.
  • such probes will have at least 30 bases and may have at least 50 bases.
  • Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
  • the coding region of the gene of the invention may be isolated by screening using the known DNA sequence to synthesize an oligonucleotide probe.
  • a labeled oligonucleotide having a sequence complementary to that of a gene of the present invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine to which members of the library the probe hybridizes.
  • polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays, inter alia.
  • polynucleotides of the invention that are oligonucleotides, derived from the sequences of SEQ ID NO: 1 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the gene identified herein in whole or in part are transcribed in infected tissue It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.
  • the polynucleotides may encode a polypeptide which is the mature protein plus additional ammo or carboxyl-terminal amino acids, or ammo acids inte ⁇ or to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance).
  • Such sequences may play a role m processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things
  • the additional ammo acids may be processed away from the mature protein by cellular enzymes
  • a precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proproteins
  • a polynucleotide of the present invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences which are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed dunng processing steps that produce active and mature forms of the polypeptide
  • a license may be required to make, use or sell the deposited materials. No such license is hereby granted.
  • the present invention further relates to a novel Staphylococcus aureus response regulator protein which has a deduced amino acid sequence of 200 amino acids in length, as set forth in Figure 2 [SEQ ID NO:2].
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.
  • the invention also relates to fragments, analogs and derivatives of these polypeptides.
  • fragment when referring to the polypeptide of Figure 2 [SEQ ID NO:2], means a polypeptide which retains essentially the same biological function or activity as such polypeptide.
  • an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.
  • the fragment, derivative or analog of the polypeptide of Figure 2 may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence.
  • a conserved or non-conserved amino acid residue preferably a conserved amino acid residue
  • substituted amino acid residue may or may not be one encoded by the genetic code
  • particularly preferred embodiments of the invention in this regard are polypeptides having the amino acid sequence of the novel response regulator protein set out in Figure 2 [SEQ ID NO:2], variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of the fragments.
  • particularly preferred embodiments of the invention in this regard are polypeptides having the amino acid sequence of SEQ ID NO 2, va ⁇ ants. analogs, derivatives and fragments thereof, and va ⁇ ants, analogs and derivatives of the fragments
  • va ⁇ ants are those that vary from a reference by conservative ammo acid substitutions Such substitutions are those that substitute a given am o acid in a polypeptide by another amino acid of like characte ⁇ stics Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic ammo acids Ala, Val, Leu and He, interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gin, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr Further particularly preferred in this regard are va ⁇ ants.
  • analogs, derivatives and fragments, and variants, analogs and derivatives of the fragments having the amino acid sequence of the polypeptide of Figure 2 [SEQ ID NO 2], in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, in any combination
  • silent substitutions, additions and deletions which do not alter the properties and activities of the polypeptide of the invention
  • conservative substitutions Most highly preferred are polypeptides having the ammo acid sequence of Figure 2 [SEQ ID NO.2] without substitutions.
  • an analogue of the polypeptide characterized by the deduced amino acid sequence of SEQ ID NO 2 retains essentially the same biological function or activity as such polypeptide
  • an analogue includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide
  • polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are pu ⁇ fied to homogeneity
  • polypeptides of the present invention include the polypeptide of Figure 2 [SEQ ID NO: 1]
  • polypeptides which have at least 70% identity to the polypeptide of Figure 2 [SEQ ID NO 2], preferably at least 80% identity to the polypeptide of Figure 2 [SEQ ID NO 2], and more preferably at least 90% similarity (more preferably at least 90% identity) to the polypeptide of Figure 2 [SEQ ID NO 2] and still more preferably at least 95% simila ⁇ ty (still more preferably at least 95% identity) to the polypeptide of Figure 2 [SEQ ID NO 2] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 am o acids and more preferably at least 50 ammo acids
  • Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.
  • polypeptides comprising fragments of SEQ ID NO:2 (Fig. 2), and fragments of variants and derivatives of the polypeptide of Figure 2 [SEQ ID NO:2].
  • a fragment is a polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides and variants or derivatives thereof.
  • fragments may be "free-standing,” i.e., not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a part or region. When comprised within a larger polypeptide, the presently discussed fragments most preferably form a single continuous region. However, several fragments may be comprised within a single larger polypeptide. For instance, certain preferred embodiments relate to a fragment of a polypeptide of the invention comprised within a precursor polypeptide designed for expression in a host and having heterologous pre- and pro- polypeptide regions fused to the amino terminus of the fragment and an additional region fused to the carboxyl terminus of the fragment. Therefore, fragments in one aspect of the meaning intended herein, refers to the portion or portions of a fusion polypeptide or fusion protein derived from SEQ ID NO:2.
  • polypeptide fragments of the invention include, for example, fragments from amino acid number about 1 to about 20, about 21 to about 40, about 41 to about 60, about 61 to about 80, about 81 to about 100, and about 101 to about 200, and any combination of these 20 amino acid fragments.
  • Truncation polypeptides include polypeptides having the amino acid sequence of Figure 2, or of variants or derivatives thereof, except for deletion of a continuous series of residues (that is, a continuous region, part or portion) that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or, as in double truncation mutants, deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl terminus.
  • Fragments having the size ranges set out above also are preferred embodiments of truncation fragments, which are especially preferred among fragments generally.
  • Degradation forms of the polypeptides of the invention in a host cell, particularly a Staphylococcus, are also preferred.
  • Preferred embodiments of the invention in this regard include fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, high antigenic index regions of the polypeptide of the invention, and combinations of such fragments.
  • Preferred regions are those that mediate activities of the polypeptides of the invention.
  • fragments that have a chemical, biological or other activity of the response regulator polypeptide of the invention including those with a similar activity or an improved activity, or with a decreased undesirable activity.
  • Further preferred polypeptide fragments are those that are antigenic or immunogenic in an animal, especially in a human.
  • the invention also relates to, among others, polynucleotides encoding the aforementioned fragments, polynucleotides that hybridize to polynucleotides encoding the fragments, particularly those that hybridize under stringent conditions, and polynucleotides, such as PCR primers, for amplifying polynucleotides that encode the fragments.
  • preferred polynucleotides are those that correspond to the preferred fragments, as discussed above. Vectors, host cells, expression
  • the present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
  • Host cells (as defined herein) can be genetically engineered to incorporate polynucleotides of the invention and express polypeptides of the present invention.
  • Introduction of a polynucleotide into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic iipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection or other methods.
  • the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transforma ⁇ ts or amplifying the genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • Polynucleotide constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.
  • the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
  • Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
  • the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector.
  • Plasmids generally are designated herein by a lower case p preceded and/or followed by capital letters and/or numbers, in accordance with standard naming conventions that are familiar to those of skill in the art.
  • Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well known, published procedures.
  • Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art.
  • vectors are those for expression of polynucleotides and polypeptides of the present invention.
  • such vectors comprise c ⁇ -acting control regions effective for expression in a host operatively linked to the polynucleotide to be expressed.
  • Appropriate rr-ms-acting factors either are supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.
  • the vectors provide for specific expression
  • Such specific expression may be inducible expression or expression only in certain types of cells or both inducible and cell-specific
  • Particularly preferred among inducible vectors are vectors that can be induced for expression by environmental factors that are easy to manipulate, such as temperature and nutrient additives
  • a va ⁇ ety of vectors suitable to this aspect of the invention, including constitutive and inducible expression vectors for use m prokaryotic and eukaryotic hosts, are well known and employed routinely by those of skill in the art
  • a great va ⁇ ety of expression vectors can be used to express a polypeptide of the invention
  • Such vectors include, among others, chromosomal, episomai and virus-de ⁇ ved vectors, e g , vectors derived from bacte ⁇ al plasmids, from bacte ⁇ ophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors de ⁇ ved from combinations thereof, such as those de ⁇ ved from plasmid and bacte ⁇ ophage genetic elements, such as cosmids and phagemids, ali may be used for expression in accordance with this aspect of the present invention
  • the approp ⁇ ate DNA sequences of the invention may be inserted into the vector in a forward or reverse o ⁇ entation by any of a va ⁇ ety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York ( 1989)
  • the DNA sequence in the expression vector is operatively linked to approp ⁇ ate expression control sequence(s), including, for instance, a promoter to direct mRNA transcription, a ⁇ bosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control elements"), to permit expression
  • promoters include, but are not limited to, the phage lambda PL promoter, the E colt lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, the protein A gene (spa) promoter and signal sequence, and other promoters known to control expression of genes in eukaryotic or prokaryotic cells or their viruses
  • expression constructs will contain sites for transcription initiation and termination, and, in the transcribed region, a ribosome binding site for translation.
  • the coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at
  • regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell.
  • Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
  • Other types of regulatory elements may also be present in the vector, for example, enhancer sequences.
  • enhancer sequences Generally, in accordance with many commonly practiced procedures, such regions will operate by regulating transcription, such as transcription factors, repressor binding sites and termination, among others.
  • Vectors for propagation and expression generally will include selectable markers and amplification regions, such as, for example, those set forth in Sambrook et al, cited above.
  • An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA poiymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence).
  • control i.e., RNA poiymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence.
  • Modification of the coding sequences may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.
  • control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above.
  • the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
  • the coding sequence may contain a signal peptide or leader sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos.
  • recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly- expressed gene to direct transcription of a downstream structural sequence
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the pe ⁇ plasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e g , stabilization or simplified purification of expressed recombinant product
  • bacterial cells such as streptococci, staphylococci, E colt, streptomyces and Bacillus subtilis cells
  • fungal cells such as yeast cells and Aspergtllus cells
  • insect cells such as Drosophila S2 and Spodoptera Sf9 cells
  • animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells, and plant cells.
  • vectors preferred for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen, pET-3 vectors (Stratagene), pDIO, ps ⁇ X174, pbsks, pBS vectors, Phagesc ⁇ pt vectors, Bluesc ⁇ pt vectors, pNH8A, pNHl ⁇ a, pNH18A, pNH46A, available from Stratagene, and ptrc99a, p K223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia, and pBR322 (ATCC 37017)
  • preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXTl and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pS VL available from Pharmacia
  • promoter-containing fragment at the restriction site upstream of the cat gene engenders production of CAT activity, which can be detected by standard CAT assays.
  • Vectors suitable to this end are well known and readily available, such as pKK232-8 and pCM7.
  • Promoters for expression of polynucleotides of the present invention include not only well known and readily available promoters, but also promoters that readily may be obtained by the foregoing technique, using a reporter gene.
  • prokaryotic promoters suitable for expression of polynucleotides and polypeptides in accordance with the present invention are the £. coli lad and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter.
  • eukaryotic promoters suitable in this regard are the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV”), and metallothionein promoters, such as the mouse metallothionein-I promoter.
  • Recombinant expression vectors will include, for example, origins of replication, a promoter preferably derived from a highly-expressed gene to direct transcription of a downstream structural sequence, and one or more selectable markers to permit isolation of vector containing cells after exposure to the vector.
  • a selectable marker may provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in £ coli.
  • Polynucleotides of the invention encoding the heterologous structural sequence of a polypeptide of the invention generally will be inserted into the vector using standard techniques so that it is operably linked to the promoter for expression.
  • the polynucleotide will be positioned so that the transcription start site is located appropriately 5' to a ribosome binding site.
  • the ribosome binding site will be 5' to the AUG that initiates translation of the polypeptide to be expressed.
  • a translation stop codon at the end of the polypeptide and there will be a polyadenylation signal in constructs for use in eukaryotic hosts
  • Transcription termination signal approp ⁇ ately disposed at the 3' end of the transcribed region may also be included in the polynucleotide construct.
  • appropriate secretion signals may be incorporated into the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals
  • the polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N- or C-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage Also, a region may be added to the polypeptide to facilitate purification Such a region may be removed p ⁇ or to final preparation of the polypeptide
  • a preferred fusion protein comprises a heterologous region from an immunoglobulin that is useful to solubihze or purify polypeptides
  • EP-A-O 464 533 discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another protein or part thereof
  • EP-A-O 464 533 discloses fusion proteins comprising various portions of constant region of immunoglobin molecules together with another protein or part thereof
  • the polypeptide of the present invention may be produced by growing host cells transformed by an expression vector desc ⁇ bed above under conditions whereby the polypeptide of interest is expressed Where the mature protein has a very hydrophobic region which leads to an insoluble product of overexpression, it may be desirable to express a truncated protein in which the hydrophobic region has been deleted.
  • polypeptides of the present invention may be glycosylated or may be non-glycosylated Polypeptides of the invention may also include an initial methionine amino acid residue.
  • the polypeptide is then isolated from the host cells and purified. If the expression system secretes the polypeptide into growth media, the polypeptide can be purified directly from the media. If the polypeptide is not secreted, it is isolated from cell lysates or recovered from the cell membrane fraction. Where the polypeptide is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product.
  • Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well know to those skilled in the art.
  • a polypeptide of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
  • This invention is also related to the use of the polynucleotides of the invention to detect complementary polynucleotides such as, for example, as a diagnostic reagent.
  • Detection of a gene characterized by the sequences of SEQ ID NO: 1 in a eukaryote, particularly a mammal, and especially a human will provide a diagnostic method for diagnosis of a disease.
  • Eukaryotes herein also "individual(s)
  • mammals particularly mammals, and especially humans, infected with an organism comprising the gene of the invention may be detected at the DNA level by a variety of techniques.
  • Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin.
  • Genomic DNA may be used directly for detection or may be amplified enzy atically by using PCR (Saiki et al, ( 1986) Nature, 324, 163-166) prior to analysis.
  • RNA or cDNA may also be used in the same ways.
  • PCR primers complementary to the nucleic acid of SEQ ID NO: 1 can be used to identify and analyze presence and/or expression of the gene.
  • characte ⁇ zation of the strain of prokaryote present in a eukaryote, particularly a mammal, and especially a human may be made by an analysis of the genotype of the prokaryote gene.
  • deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence
  • Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA or alternatively, radiolabeled antisense DNA sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNaseA digestion or by differences in melting temperatures.
  • Sequence differences between a reference gene and genes having mutations also may be revealed by direct DNA sequencing.
  • cloned DNA segments may be employed as probes to detect specific DNA segments.
  • the sensitivity of such methods can be greatly enhanced by approp ⁇ ate use of PCR or another amplification method.
  • a sequencing primer is used with double-stranded PCR product or a single- stranded template molecule generated by a modified PCR.
  • the sequence determination is performed by conventional procedures with radiolabeled nucleotide or by automatic sequencing procedures with fluorescent-tags.
  • DNA sequence differences may be achieved by detection of alteration in electrophoretic mobility of DNA fragments in gels, with or without denatu ⁇ ng agents. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis DNA fragments of different sequences may be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al, (1985) Science, 230, 1242) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S I protection or the chemical cleavage method (e g.. Cotton et al, ( 1985) Proc Natl. Acad. Sci. USA, 85, 4397-4401).
  • the detection of a specific DNA sequence may be achieved by methods such as hyb ⁇ dization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes, e.g., rest ⁇ ction fragment length polymorphisms (RFLP) and Southern blotting of genomic DNA.
  • restriction enzymes e.g., rest ⁇ ction fragment length polymorphisms (RFLP) and Southern blotting of genomic DNA.
  • mutations also can be detected by in situ analysis.
  • RNA or cDNA may also be used for the same purpose, PCR or RT- PCR.
  • PCR primers complementary to the nucleic acid encoding SEQ ID NO:2 can be used to identify and analyze mutations. Suitable primers may include fragments of SEQ ID NO:l, preferably of at least 15 base pairs in length, as well as sequences complementary thereto. The primers may be used to amplify the gene isolated from the individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be diagnosed.
  • the invention provides a process for diagnosing disease, preferably bacterial infections, more preferably Staphylococcus, comprising determining from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Figure 1 [SEQ ID NO: 1].
  • Increased expression of the polynucleotide of the invention can be measured using any one of the methods well known in the art for the quantation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
  • Polypeptide assays The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the proteins and polypeptides of the invention in cells and tissues, including determination of normal and abnormal levels.
  • a diagnostic assay in accordance with the invention for detecting over-expression of a protein of the invention compared to normal control tissue samples may be used to detect the presence of an infection, for example.
  • Assay techniques that can be used to determine levels of a protein of the invention, in a sample derived from a host are well- known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these ELISAs frequently are preferred.
  • An ELISA assay initially comprises preparing an antibody specific to a polypeptide of the invention, particularly a polypeptide characterized by the amino acid sequence of SEQ ID NO:2 or a derivative thereof.
  • the antibody is a monoclonal antibody.
  • a reporter antibody generally is prepared which binds to the monoclonal antibody.
  • the reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example, horseradish peroxidase enzyme.
  • polypeptides, their fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto.
  • the present invention includes, for examples monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library.
  • Antibodies generated against the polypeptides corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
  • any technique known in the art which provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C, (1975) Nature 256, 495-497; Kozbor et al, (1 83) Immunology Today 4: 72; Cole et al., pg. 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc. (1985).
  • phage display technology could be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v- genes of lymphocytes from humans screened for possessing anti-Fbp or from naive libraries (McCafferty, J. et al, ( 1990), Nature, 348, 552-554; Marks, J. et al, ( 1992) Biotechnology, 10, 779-783).
  • the affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al, ( 1991) Nature, 352, 624-628). If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.
  • the above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or purify the polypeptide of the present invention by attachment of the antibody to a solid support for isolation and/or purification by affinity chromatography.
  • antibodies against the polypeptides of the invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially Staphylococcal infections.
  • Polypeptide derivatives include antigenically, epitopically or immunologically equivalent derivatives which form a particular aspect of this invention.
  • the term "antigenically equivalent derivative” as used herein encompasses a polypeptide or its equivalent which will be specifically recognised by certain antibodies which, when raised to the protein or polypeptide according to the present invention, interfere with the immediate physical interaction between pathogen and mammalian host.
  • the term “immunologically equivalent derivative” as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.
  • the polypeptide such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
  • the fusion protein may provide stability to the polypeptide.
  • the antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).
  • BSA bovine serum albumin
  • KLH keyhole limpet haemocyanin
  • a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.
  • the antibody or derivative thereof is modified to make it less immunogenic in the individual.
  • the antibody may most preferably be "humanized”; where the compiimentarity determining region(s) of the hybridoma- derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones, P. et al, ( 1986), Nature 321, 522-525 or Tempest et al, ( 1991) Biotechnology 9, 266-273.
  • a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al, (1992) Hum Mol Genet, 1:363, Manthorpe et al, (1963) Hum. Gene Ther., 4, 419), delivery of DNA complexed with specific protein carriers (Wu et al, ( 1989) J Biol Chem, 264, 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, (1986) Proc. Natl. Acad.
  • a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al, (1992) Hum Mol Genet, 1:363, Manthorpe et al, (1963) Hum. Gene Ther., 4, 419), delivery of DNA complexed with specific protein carriers (Wu et al, ( 1989) J Biol Chem, 264, 16985),
  • This invention also provides a method for identification of molecules, such as binding molecules, that bind the polynucleotides and polypeptides of the invention.
  • Genes encoding such binding proteins can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Such methods are described in many laboratory manuals such as, for instance, Coligan et al. Current Protocols in Immunology 1(2): Chapter 5 ( 1991 ).
  • a labeled ligand can be photoaffinity linked to a cell extract.
  • Polypeptides of the invention also can be used to assess the binding capacity of these molecules in cells or in cell-free preparations.
  • Polypeptides of the invention may also be used to assess the binding or small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics.
  • the invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of the polypeptides or polynucleotides of the invention, such as their interaction with the binding molecules of the invention.
  • a synthetic reaction mix such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds a polynucleotide or polypeptide of the invention.
  • the preparation is incubated with a labeled polypeptide or polynucleotide of the invention in the absence or the presence of a candidate molecule which may be an agonist or antagonist.
  • the ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labeled ligand.
  • Molecules which bind gratuitously are most likely to be good antagonists.
  • Molecules that bind well and elicit effects that are the same as or closely related to the polynucleotides or polypeptides of the invention are agonists
  • the effects, e g , anti-bacte ⁇ al effects, of potential agonists and antagonists may be measured, for instance, by determining activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of the polynucleotides and polypeptides of the invention or molecules that elicit the same effects as the compositions of the invention
  • Reporter systems that may be useful in this regard include but are not limited to colo ⁇ met ⁇ c labeled substrate converted into product, a reporter gene that is responsive to changes in activity, and binding assays known in the art
  • an assay for antagonists is a competitive assay that combines a polypeptide or polynucleotide of the invention and a potential antagonist with membrane- bound molecules which bind the polynucleotides or polypeptides of the invention, recombinant binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under approp ⁇ ate conditions for a competitive inhibition assay
  • the polynucleotides and polypeptides of the invention can be labeled, such as by radioactivity or a colo ⁇ met ⁇ c compound, such that the number of molecules of the invention bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist
  • Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polypeptide of the invention and thereby inhibit or extinguish its activity
  • Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds
  • Potential antagonists include a small molecule which binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented
  • small molecules include but are not limited to small organic molecules, peptides or peptide- ke molecules
  • Preferred potential antagonists include antisense molecules (see Okano, ( 1991) J Neurochem , 56, 560, OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton. FL ( 1988), for a desc ⁇ ption of these molecules)
  • Preferred potential antagonists include compounds related to and de ⁇ vatives of the gene of the invention.
  • the invention provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection
  • the molecules of the invention may be used 1) in the prevention of adhesion of bacteria, in particular gram positive bacte ⁇ a, to mammalian extracellular matrix proteins on m-dwelling devices or to extracellular matrix proteins in wounds, n) to block response regulator protein mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine et al, ( ⁇ 992) Infect Immun , 60, 221 1 , in) to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial response regulator proteins which mediate tissue damage, iv) to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques
  • the antagonists and agonists may be employed for instance to inhibit bacterial infections, particularly Staphylococcal infections
  • this invention provides a method of screening drugs to identify those which 1) interfere with the interaction of the response regulator with a histidine kinase, the method comprising incubating the response regulator with histidine kinase in the presence of the drug and measu ⁇ ng the ability of the drug to block this interaction, u) interfere with the ability of the response regulator to catalyse the transfer of phosphate group from the histidine kinase to itself, the method comprising incubating the response regulator with drug and measuring the ability of the response regulator to catalyse the removal of phosphate from phosphorylated histidine kinase, and/or in) interfere with the ability of the molecule to autodephosphorylate itself once the phosphate had been transferred, the method comprising incubating the phosphorylated response regulator with drug and measuring the ability of the response regulator to catalyse the autodephosphoryiation
  • the histidine kinase is preferably the cognate histidine kinase of
  • aureus but may be from another microorganism, e.g.. Bacillus.
  • Bacillus e.g. Bacillus.
  • the genes for a histidine kinase and its cognate response regulator are found close together on the chromosome so a suitable histidine kinase may conveniently be identified by further sequencing along the chromosome.
  • the invention also relates to inhibitors identified thereby.
  • Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with the gene of the invention, or a fragment or variant thereof, adequate to produce antibody to protect said individual from infection, particularly bacterial infection and most particularly Staphylococcal infections.
  • Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises, through gene therapy, delivering gene characterized by the sequences of SEQ ID NOs: 1 and 2, or a fragment or a variant thereof, for expressing the gene, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody to protect said individual from disease.
  • a further aspect of the invention relates to an immunological composition which, when introduced into a host capable or having induced within it an immunological response, induces an immunological response in such host to a gene characterized by the polynucleotide sequences of the invention or protein coded therefrom, wherein the composition comprises a recombinant gene or protein coded therefrom comprising DNA which codes for and expresses an antigen of said gene or protein coded therefrom.
  • the gene or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties.
  • fused recombinant protein preferably further comprises an antigenic co-protein, such as Glutathione-S- transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof.
  • GST Glutathione-S- transferase
  • the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system.
  • the co-protein may be attached to either the amino or carboxy terminus of the first protein.
  • polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue.
  • tissue damage examples include wounds in skin or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of in-dwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.
  • the present invention also includes a vaccine formulation which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostatics and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
  • the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
  • compositions comprising the polynucleotide or the polypeptides discussed above or the agonists or antagonists.
  • the polypeptides of the present invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject.
  • compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient.
  • Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glyceroi, ethanol and combinations thereof.
  • the formulation should suit the mode of administration.
  • Kits The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration. Administration
  • Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
  • compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.
  • compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications.
  • the compositions are administered in an amount of at least about 10 ⁇ g/kg body weight. In most cases they will be administered in an amount not in excess of about 8 mg/kg body weight per day. Preferably, in most cases, dose is from about 10 ⁇ g/kg to about 1 mg kg body weight, daily. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like.
  • the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic
  • the composition may be formulated for topical application, for example, in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams
  • Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions
  • Such carriers may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation.
  • In-dwelling devices include surgical implants, prosthetic devices and catheters, i e , devices that are introduced to the body of an individual and remain in position for an extended time Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, u ⁇ nary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters, etc
  • the composition of the invention may be administered by injection to achieve a systemic effect against relevant bacte ⁇ a shortly before insertion of an in-dwell
  • compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis
  • the composition of the invention may be used to bathe an in-dwelling device immediately before insertion
  • the active agent will preferably be present at a concentration of l mg/ml to lOmg/ml for bathing of wounds or in-dwelling devices.
  • a vaccine composition is conveniently in injectable form Conventional adjuvants may be employed to enhance the immune response.
  • a suitable unit dose for vaccination is 0 5-5 mg/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks
  • the antibodies described above may also be used as diagnostic reagents to detect the presence of bacteria containing the response regulator protein of the invention
  • Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures.
  • DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA poiymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • Method 2 Total cellular DNA is partially hydrolysed with a combination of four restriction enzymes (Rsal, Pall, Alul and Bsh 12351) and size-fractionated according to standard procedures.
  • EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • the sequences of the novel compounds are provided in Fig. 1, SEQ ID NO: 1.
  • the amino acid sequence of SEQ ID NO:2 is the translated open reading frame of SEQ ID NO: l which displays homology (28% identity) to the DegU regulatory protein from Bacillus subtilis.
  • TCGAACGTTC TTTTAAAACA TATGCATCCA CATCATTCAC AACTGCTTTT TCAAAGTATC 360 CCGGTCTTTT AAAAGTTGTT ACAATAATCA CTTTAATATT CAAATGCTTT TTTCTAATTT 420
  • GATTATATTC TTCAATAAGT TTCATTGCAT CGAGACCATT ATCAGTATCT GCTAAAATTT 540
  • CAAAATCACC ATGTAGTTTA ATTAATTGAA CCATTGCCTG TCGTAACATA TTTTGATCTT 600
  • NCIMB National Collection of Industrial and Marine Bacteria L t d.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP96943225A 1995-12-22 1996-12-20 Komponente eines signalübertragungssystems von staphylococcus. Withdrawn EP0868515A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9526355.4A GB9526355D0 (en) 1995-12-22 1995-12-22 Novel compounds
GB9526355 1995-12-22
PCT/GB1996/003204 WO1997023621A1 (en) 1995-12-22 1996-12-20 Component of a staphylococcus signal transduction system

Publications (1)

Publication Number Publication Date
EP0868515A1 true EP0868515A1 (de) 1998-10-07

Family

ID=10785950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96943225A Withdrawn EP0868515A1 (de) 1995-12-22 1996-12-20 Komponente eines signalübertragungssystems von staphylococcus.

Country Status (4)

Country Link
EP (1) EP0868515A1 (de)
JP (1) JP2000503529A (de)
GB (1) GB9526355D0 (de)
WO (1) WO1997023621A1 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466685A (en) * 1993-05-13 1995-11-14 Johnson & Johnson Inhibition of expression of beta-lactamase using esters of fatty acid alcohols

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9723621A1 *

Also Published As

Publication number Publication date
GB9526355D0 (en) 1996-02-21
WO1997023621A1 (en) 1997-07-03
JP2000503529A (ja) 2000-03-28

Similar Documents

Publication Publication Date Title
US5846772A (en) Two component signal transduction system response regulator polynucleotides of Staphylococcus aureus
US6217862B1 (en) TCTS response regulator
US5854020A (en) TCSTS polynucleotides
EP0843016A2 (de) Staphylococcus FabD (malonylCoA:ACP transacylase) Protein
US5962259A (en) Response regulator polynucleotides
US5955304A (en) DivIB
US6084086A (en) TCSTS polynucleotides
US6365159B1 (en) Spo-rel
EP0816502A2 (de) Mur A-1, ein UDP-N-Acetylglucosamine-Enolpyruvyltransferase, aus Streptococcus pneumoniae
US6004556A (en) Staphylococcus aureus RSBU-1
EP0902087A2 (de) Histidine kinase
EP0877755A1 (de) Zwei-komponenten regulator-polypeptide der signaltransduktions-antwort aus staphylococcus aureus
CA2242313A1 (en) Signal recognition particle polypeptides and polynucleotides
US5942419A (en) RsbW-1 encoding nucleic acids
US6136556A (en) TCTS response regulator
US6310192B1 (en) SigB
US20020076776A1 (en) Novel TCTS response regulator
US6228612B1 (en) Compounds
EP0868515A1 (de) Komponente eines signalübertragungssystems von staphylococcus.
US6297358B1 (en) RsbV-1 from staphylococcus aureus
EP0838525A2 (de) Streptococcus pneumoniae Polypeptide greA
JP2000504207A (ja) スタフィロコッカス・アウレウス由来の２成分シグナルトランスダクション応答レギュレーターポリペプチド
EP1329510A2 (de) FabD aus Staphylococcus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020228